Catalent has entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO (pralsetinib). GAVRETO is a new therapy developed by Blueprint Medicines for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

This agreement will continue Catalent’s involvement in the GAVRETO program, which has been supported by Catalent’s Nottingham, U.K., site since 2015.
 

GAVRETO is a once-daily oral RET-targeted therapy designed to selectively and potently inhibit RET alterations that drive many cancer types, including approximately one to two percent of patients with metastatic NSCLC. Currently, RET is one of seven NSCLC biomarkers that can be targeted with an FDA-approved therapy.

“We have a long-standing relationship with Blueprint Medicines, and this approval marks an amazing accomplishment, reflecting the hard work, dedication and determination of the entire team,” commented Jonathan Arnold, President of Oral and Specialty Delivery at Catalent. “The expertise that our scientists in Nottingham brought to the development program supported Blueprint Medicines’ efforts to rapidly gain regulatory approval, and through expedient tech transfer within our company’s global network, our team in Kansas City can effectively support commercial supply.”

In February 2020, Catalent announced a commercial supply agreement for Blueprint Medicines’ AYVAKIT (avapritinib) for the treatment of unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.